Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®Phase 3 trial of ...
These questions reflect a broader regulatory assumption: that platforms have matured technologically to support continuous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback